India to United States: Citalopram Export Trade Route
India has recorded 953 verified shipments of Citalopram exported to United States, representing a combined trade value of $61.3M USD. This corridor is served by 14 active Indian exporters, with an average shipment value of $64.4K USD. The leading Indian exporter is MYLAN LABORATORIES LIMITED, which accounts for 21% of total export value with 87 shipments worth $13.0M USD. On the buying side, TORRENT PHARMA INC is the largest importer in United States with $11.8M USD in purchases. The top 3 suppliers — MYLAN LABORATORIES LIMITED, TORRENT PHARMACEUTICALS LTD, AUROBINDO PHARMA LTD — together control 62% of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to United States Citalopram corridor is one of India's established pharmaceutical export routes, with 953 shipments documented worth a combined $61.3M USD. The route is dominated by MYLAN LABORATORIES LIMITED, which alone accounts for roughly 21% of all export value, reflecting the consolidated nature of India's citalopram manufacturing sector.
Across 14 active suppliers, the average shipment value stands at $64.4K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (69%) and air (18%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.
Shipment activity peaks during July–September, with an average transit time of 19 days port-to-port. The route has recorded an annual growth rate of 24.8%, placing it at rank #2 among India's top citalopram export destinations globally.
On the import side, key buyers of Indian citalopram in United States include TORRENT PHARMA INC, MYLAN PHARMACEUTICALS INC, AUROLOGISTICS LLC (AUROBINDO PHARMA and 52 others. TORRENT PHARMA INC is the single largest importer with 108 shipments valued at $11.8M USD.
Route Characteristics
- Average transit19 days
- Peak seasonQ3
- Primary modeMulti-modal
- Top portHYDERABAD ICD
Market Position
- Global rank#2
- Annual growth+24.8%
- Demand growth+20.9%
- Regulatory ease70/100
Top 10 Indian Citalopram Exporters to United States
Showing top 10 of 14 Indian suppliers exporting Citalopram to United States, ranked by total trade value (USD)
| Rank | Supplier (Indian Exporter) | Shipments | Total Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED Avg $149.4K per shipment | 87 | $13.0M | 21.2% |
| 2 | TORRENT PHARMACEUTICALS LTD Avg $112.1K per shipment | 112 | $12.6M | 20.5% |
| 3 | AUROBINDO PHARMA LTD Avg $61.6K per shipment | 201 | $12.4M | 20.2% |
| 4 | AUROBINDO PHARMA LIMITED Avg $79.8K per shipment | 123 | $9.8M | 16.0% |
| 5 | GRAVITI PHARMACEUTICALS PRIVATE LIMITED Avg $20.9K per shipment | 258 | $5.4M | 8.8% |
| 6 | TORRENT PHARMACEUTICALS LIMITED Avg $78.9K per shipment | 66 | $5.2M | 8.5% |
| 7 | CIPLA LIMITED Avg $69.8K per shipment | 18 | $1.3M | 2.0% |
| 8 | MACLEODS PHARMACEUTICALS LTD Avg $22.0K per shipment | 41 | $904.0K | 1.5% |
| 9 | HETERO LABS LIMITED Avg $16.7K per shipment | 27 | $451.1K | 0.7% |
| 10 | HETERO LABS LIMITED Avg $35.8K per shipment | 7 | $250.7K | 0.4% |
This table shows the top 10 of 14 Indian companies exporting citalopram to United States, ranked by total trade value. The listed exporters are: MYLAN LABORATORIES LIMITED, TORRENT PHARMACEUTICALS LTD, AUROBINDO PHARMA LTD, AUROBINDO PHARMA LIMITED, GRAVITI PHARMACEUTICALS PRIVATE LIMITED, TORRENT PHARMACEUTICALS LIMITED, CIPLA LIMITED, MACLEODS PHARMACEUTICALS LTD, HETERO LABS LIMITED, HETERO LABS LIMITED. MYLAN LABORATORIES LIMITED is the dominant supplier with 87 shipments worth $13.0M USD, giving it a 21% market share. The top 3 suppliers together account for 62% of the total trade value on this route.
Showing top 10 of 14 total Indian exporters on the India to United States Citalopram export route.
Top 10 Citalopram Importers in United States
Showing top 10 of 55 known buyers in United States receiving Citalopram shipments from India, ranked by import value
On the receiving end of this trade route, the leading importers of Indian citalopram in United States include TORRENT PHARMA INC, MYLAN PHARMACEUTICALS INC, AUROLOGISTICS LLC (AUROBINDO PHARMA, AUROLOGISTICS LLC AUROBINDO PHARM, AUROLOGISTICS LLC, among 55 total buyers. The largest importer is TORRENT PHARMA INC, accounting for $11.8M USD across 108 shipments — representing 19% of all citalopram imports from India on this route.
| Rank | Importer / Buyer | Shipments | Import Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | TORRENT PHARMA INC | 108 | $11.8M | 19.2% |
| 2 | MYLAN PHARMACEUTICALS INC | 45 | $11.0M | 18.0% |
| 3 | AUROLOGISTICS LLC (AUROBINDO PHARMA | 77 | $5.3M | 8.7% |
| 4 | AUROLOGISTICS LLC AUROBINDO PHARM | 36 | $3.9M | 6.4% |
| 5 | AUROLOGISTICS LLC | 49 | $3.2M | 5.2% |
| 6 | RISING PHARMA HOLDINGS, INC. | 174 | $3.1M | 5.1% |
| 7 | TORRENT PHARMA INC Importer EIN 36-4547412 | 31 | $2.9M | 4.7% |
| 8 | AUROLOGISTICS LLC, (AUROBINDO PHARM | 26 | $2.2M | 3.5% |
| 9 | XXRREXX PHXXMA XXC XXMPOXXER XXIN XX6 4XX741XX | 25 | $1.8M | 2.9% |
| 10 | RISING PHARMA HOLDINGS INC | 56 | $1.6M | 2.6% |
Showing top 10 of 55 Citalopram importers in United States on this route.
Top 10 Citalopram Formulations Imported by United States
Showing top 10 of 564 product formulations shipped on the India to United States Citalopram route, ranked by trade value
United States imports a wide range of citalopram formulations from India, spanning tablets, capsules, suspensions, and combination drugs. The top formulation — CITALOPRAM TABLETS USP 40 MG 100BT PACKS56314 — accounts for $9.1M USD across 1 shipments. There are 564 distinct product descriptions in the dataset, reflecting the variety of dosage forms and strengths imported.
| Rank | Product Formulation | Shipments | Trade Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | CITALOPRAM TABLETS USP 40 MG 100BT PACKS56314 | 1 | $9.1M | 14.8% |
| 2 | ESCITALOPRAM TABLETS USP 20MG | 24 | $2.1M | 3.5% |
| 3 | OTHER - ESCITALOPRAM TABLETS USP 20MG (NDC NO. 13668-137-10) ( ESCITALOPRAM 20MG) NOS SIZE 1X1000 TABLETS | 9 | $1.8M | 3.0% |
| 4 | OTHER - ESCITALOPRAM TABLETS USP 20MG (NDC NO. 13668-137-01) ( ESCITALOPRAM 20MG) NOS SIZE 1X1000 TABLETS | 6 | $1.4M | 2.2% |
| 5 | ESCITALOPRAM TABLETS USP 10 MG | 20 | $1.4M | 2.2% |
| 6 | ESCITALOPRAM TABLETS USP 10MG (ESCITALOPRAM TABLETS USP 10 MG) 500'S | 7 | $1.1M | 1.8% |
| 7 | ESCITALOPRAM 20 MG TABLETS (ESCITALOPRAMTABLETS USP 20 MG) 500'S | 8 | $1.1M | 1.8% |
| 8 | CITALOPRAM TABLETS USP 40MG | 8 | $1.0M | 1.6% |
| 9 | ESCITALOPRAM TABLETS USP 10MG | 10 | $811.5K | 1.3% |
| 10 | ESCITALOPRAM 20 MG TABLETS (ESCITALOPRAM | 5 | $643.1K | 1.0% |
Showing top 10 of 564 Citalopram formulations imported by United States on this route.
Shipping & Logistics Analysis
Freight mode split and port-of-origin breakdown
Freight Mode Distribution
Balanced freight mix — 69% sea for bulk, 18% air for urgent orders.
Top Ports of Origin
HYDERABAD ICD handles the highest volume with 247 shipments. Transit time averages 19 days by sea.
Market Dynamics
India's citalopram exports to United States are driven primarily by a handful of large-scale manufacturers. MYLAN LABORATORIES LIMITED with 87 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 14 active exporters signals a competitive but concentrated market — buyers in United States benefit from supplier diversity while the top tier handles the majority of volume.
The top 3 suppliers — MYLAN LABORATORIES LIMITED, TORRENT PHARMACEUTICALS LTD, AUROBINDO PHARMA LTD — together account for 62% of total trade value on this route. The average shipment value of $64.4K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.
Beyond the primary product category, shipments on this route include closely related formulations such as escitalopram tablets usp 20mg and other - escitalopram tablets usp 20mg (ndc no. 13668-137-10) ( escitalopram 20mg) nos size 1x1000 tablets, suggesting that buyers in United States tend to consolidate orders across related product lines from the same Indian supplier.
On the buying side, TORRENT PHARMA INC is the largest importer with 108 shipments worth $11.8M USD — representing 19% of all citalopram imports from India on this route. A total of 55 buyers are active on this corridor.
Route Statistics
- Trade Volume
- $61.3M
- Avg. Shipment
- $64.4K
- Suppliers
- 14
- Buyers
- 55
- Transit (Sea)
- ~19 days
- Annual Growth
- +24.8%
Related Analysis
Reverse Direction
United States → India — Citalopram (Import)Other Citalopram Routes
Unlock the Full India to United States Citalopram Dataset
TransData Nexus provides verified shipment-level records, supplier contact details, HS code breakdowns, real-time pricing benchmarks, and regulatory compliance guides for 953 shipments on this route.
Frequently Asked Questions — India to United States Citalopram Trade
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which Indian companies export Citalopram to United States?
The leading Indian exporters of Citalopram to United States are MYLAN LABORATORIES LIMITED, TORRENT PHARMACEUTICALS LTD, AUROBINDO PHARMA LTD. MYLAN LABORATORIES LIMITED holds the largest market share at approximately 21% of total trade value on this route.
Q What is the total value of Citalopram exports from India to United States?
India exports Citalopram to United States worth approximately $61.3M USD across 953 recorded shipments. The average value per shipment is $64.4K USD.
Q Which ports does India use to ship Citalopram to United States?
The most active port of origin is HYDERABAD ICD with 247 shipments. Indian exporters primarily use a mix of sea and air freight for this route, with 69% of shipments going by sea and 18% by air.
Q How long does shipping take from India to United States for Citalopram?
The average transit time for Citalopram shipments from India to United States is approximately 19 days. Sea freight typically takes longer, while air freight can reduce this significantly for urgent orders. Peak shipping activity is observed during July–September.
Q Is the India to United States Citalopram trade route growing?
Yes — this trade corridor has seen an annual growth rate of approximately 24.8% with demand growth tracking at 20.9%. The route is ranked #2 among India's top Citalopram export destinations globally.
Q How many suppliers are active on the India to United States Citalopram route?
There are currently 14 active Indian suppliers exporting Citalopram to United States. The market is moderately concentrated with MYLAN LABORATORIES LIMITED accounting for 21% of total shipment value.
Q Who are the main importers of Citalopram from India in United States?
The leading importers of Indian Citalopram in United States include TORRENT PHARMA INC, MYLAN PHARMACEUTICALS INC, AUROLOGISTICS LLC (AUROBINDO PHARMA, AUROLOGISTICS LLC AUROBINDO PHARM, AUROLOGISTICS LLC. TORRENT PHARMA INC is the largest buyer with 108 shipments worth $11.8M USD.
Official References & Regulatory Resources
- India Trade Statistics (DGFT)
- Invest India — Pharma Sector
- WCO HS Nomenclature
- Ministry of Commerce — Pharma Exports
- Pharmexcil
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Route Identification: India to United States export trade corridor identified from Indian Customs (DGFT) records for Citalopram.
- 2.Supplier/Buyer Matching: 14 Indian exporters and 55 importers in United States matched using name normalization.
- 3.Value Aggregation: Total export value aggregated from 953 verified shipping bill records. Values are FOB in USD.
- 4.Market Share Analysis: Each supplier and buyer contribution calculated as a percentage of total route value. Statistical normalization applied to ensure accurate representation across varying shipment sizes.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
953 Verified Shipments
14 Indian exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists